Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

While both Wegovy and Ozempic list “headache” as a common side effect that was found during the drugs’ clinical trials, many ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Amanda Bynes has given fans a glimpse into her latest jewelry addition. Posting via her Instagram Stories on Thursday, July ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...